Policy & Regulation
Onco360 to dispense Inrebic (fedratinib) under specialty pharmacy network with Celgene
19 August 2019 -

Oncology pharmacy Onco360 said on Friday that it has signed a specialty pharmacy network partnership with Celgene for its Inrebic product.

Under the specialty pharmacy network partnership, Onco360 has been selected as a specialty pharmacy provider for for Celgene's new product Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF).

MF is a serious and rare bone marrow disorder that disrupts the body's normal production of blood cells. Bone marrow is gradually replaced with fibrous scar tissue, which limits the bone marrow to make red blood cells, leading to anemia, fatigue among other symptoms.

Based on Celgene's randomized, Phase III JAKARTA trial, the Inrebic administration resulted in significantly improved MF-associated symptom burden (40% vs 9%) and significantly improved spleen response rates (37% vs 1%) compared to a placebo.

In conjunction, Inrebic is manufactured by Celgene and was approved by the US FDA on 16 August 2019.

Login
Username:

Password:


Related Headlines